simvastatin has been researched along with Cirrhosis, Liver in 42 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.38) | 18.2507 |
| 2000's | 6 (14.29) | 29.6817 |
| 2010's | 20 (47.62) | 24.3611 |
| 2020's | 15 (35.71) | 2.80 |
| Authors | Studies |
|---|---|
| Abraldes, JG; Alessandria, C; Beuers, U; Campion, D; Caraceni, P; Carol, M; Davis, MM; de Wit, K; Durand, F; Francoz, C; Ginès, P; Jiménez, C; Juanola, A; Kamath, PS; Kazankov, K; Lozano, JJ; Ma, AT; Mookerjee, RP; Morales-Ruiz, M; Napoleone, L; Piano, S; Pose, E; Sidorova, J; Solà, E; Tonon, M; Trebicka, J; Uschner, F; Vargas, V; Watson, H; Zaccherini, G | 1 |
| Byun, KS; Hwang, JW; Jung, YK; Kang, SH; Kim, BH; Kim, JH; Kim, MJ; Lee, YS; Park, HC; Seo, YS; Um, SH; Yeon, JE; Yim, H; Yim, HJ | 1 |
| Li, S; Xie, B; Zhang, H; Zhang, Q | 1 |
| Duan, BW; Jiang, HL; Lee, J; Li, L; Oh, YK; Wang, XH; Xing, L; Zhang, CL; Zhang, LF | 1 |
| Gardner, I; Hatley, O; Jamei, M; Johnson, TN; Small, BG | 1 |
| Simon, TG | 1 |
| Abraldes, JG; Alessandria, C; Amin, A; Andrade, RJ; Angeli, P; Bernardi, M; Beuers, U; Campion, D; Caraceni, P; Carol, M; de Wit, K; Domenech, G; Durand, F; Ferrero, J; Ginès, P; Jimenez, C; Kamath, PS; Llopis, M; Mookerjee, RP; Napoleone, L; Piano, S; Pich, J; Pose, E; Roux, O; Solà, E; Torres, F; Trebicka, J; Uschner, FE; Vargas, V; Zaccherini, G | 1 |
| Goel, A; Lavezo, J; Podboy, A; Wong, K | 1 |
| Arora, V; Choudhary, A; Jindal, A; Kumar, G; Sarin, SK; Vijayaraghavan, R | 1 |
| Andrade, F; Augustin, S; Barberá, A; Bravo, M; Genescà, J; Gil, M; Gracia-Sancho, J; Hide, D; Martell, M; Rafael, D; Raurell, I; Schwartz, S; Vargas, V | 1 |
| Álvarez, D; Cartier, M; Marino, M; Míguez, C; Muñoz, AE; Pollarsky, F; Romero, G; Salgado, P; Vázquez, H | 1 |
| Armas Flórez, CD; Concepción-Zavaleta, MJ; Gonzáles Yovera, JG; Moreno Marreros, DM | 1 |
| Abraldes, JG; Al-Karaghouli, M; Cabrera Garcia, L; Kalainy, S; Sung, S | 1 |
| Albrecht, J; Aytaman, A; Baffy, G; Bajaj, J; Garcia-Tsao, G; Hernaez, R; Hunt, K; Ioannou, G; Johnson, K; Kanwal, F; Kaplan, DE; Lee, TH; Mehta, R; Monto, A; Pandya, P; Schaubel, D; Taddei, TH | 1 |
| Albrahim, T; Alonazi, MA | 1 |
| Bosch, J; Iwakiri, Y | 1 |
| Baiges, A; Bosch, J; Hernández-Gea, V | 1 |
| Baik, SK; Cha, SK; Chang, SJ; Cho, MY; Jang, YO; Kim, KS; Kim, MY; Kim, SH; Park, KS | 1 |
| Bosch, J; Fernández-Iglesias, A; Garcia-Calderó, H; García-Pagán, JC; Gracia-Sancho, J; Lafoz, E; Rodrigues de Oliveira, J; Tripathi, DM; Viegas Haute, G; Vilaseca, M | 1 |
| Björnsson, E; Enders, F; Lindor, KD; Suwanwalaikorn, S; Treeprasertsuk, S | 1 |
| Atta, HM; Azzam, M; Motawi, TM; Sadik, NA | 1 |
| Shen, C; Wang, W; Wang, Y; Zhao, C; Zhen, Z; Zhou, J | 1 |
| Abraldes, JG; Bosch, J; García-Cardena, G; García-Pagán, JC; Gracia-Sancho, J; Maeso-Díaz, R; Marrone, G | 1 |
| Ray, K | 1 |
| Schierwagen, R; Trebicka, J | 1 |
| Pariente, A | 1 |
| Abraldes, JG; Tandon, P | 1 |
| da Silva, AC; Kunz, DG; Marchiori, RC; Mattos, DE; Pollo-Flores, P; Rezende, GF; Santos, UC; Soldan, M | 1 |
| de-Madaria, E | 1 |
| Abraldes, JG; Albillos, A; Aracil, C; Bosch, J; Calleja, JL; Castellote, J; García-Pagán, JC; Genesca, J; Hernandez-Guerra, M; Rodriguez, M; Torres, F; Turnes, J; Villanueva, C | 1 |
| Abraldes, JG; Bosch, J; García-Calderó, H; García-Pagán, JC; Gracia-Sancho, J; Lozano, JJ; Meireles, CZ; Pasarin, M | 1 |
| Borgsteede, SD; Drenth, JP; Weersink, RA | 1 |
| Abraldes, JG; Albillos, A; Bañares, R; Bosch, J; García-Pagán, JC; González, R; Turnes, J | 1 |
| Bilbao, I; Blanco, L; Caralt, M; Castells, L; Charco, R; Dopazo, C; Lázaro, JL; Sapisochin, G | 1 |
| Jo, YJ; Jun, DW; Kang, JS; Kim, EK; Kim, KT; Kim, SH; Park, JH; Park, YS; Son, BK | 1 |
| Baek, SD; Jang, SJ; Kim, TH; Lee, HS; Leem, J; Ok, TJ; Park, SE; Park, SJ | 1 |
| Cao, W; Wang, W; Yan, L; Zhao, CY | 1 |
| Geerts, A; Hellemans, K; Kisanga, E; Rombouts, K; Schuppan, D; Wielant, A | 1 |
| Abraldes, JG; Berzigotti, A; Bosch, J; Fernández, M; Garca-Pagán, JC; Rodés, J; Turnes, J; Zafra, C | 1 |
| Abraldes, JG; Bosch, J; García-Calderó, H; García-Pagán, JC; Graupera, M; Rodríguez-Vilarrupla, A; Zafra, C | 1 |
| Horiuchi, Y; Maruoka, H | 1 |
| Caldwell, SH; Hespenheide, EE; von Borstel, RW | 1 |
5 review(s) available for simvastatin and Cirrhosis, Liver
| Article | Year |
|---|---|
Simvastatin is Efficacious in Treating Cirrhosis: A Meta-analysis.
Topics: Cholesterol; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Cirrhosis; Simvastatin; Triglycerides | 2022 |
A systematic review on pharmacokinetics, cardiovascular outcomes and safety profiles of statins in cirrhosis.
Topics: Atorvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Cirrhosis; Pravastatin; Simvastatin | 2021 |
The portal hypertension syndrome: etiology, classification, relevance, and animal models.
Topics: Adrenergic beta-Antagonists; Animals; Ascites; Carcinoma, Hepatocellular; Early Detection of Cancer; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Healthy Lifestyle; Hemorrhage; Hepatic Encephalopathy; Hepatic Veins; Humans; Hypertension, Portal; Hypolipidemic Agents; Ligation; Liver Cirrhosis; Liver Neoplasms; Models, Animal; Prognosis; Simvastatin | 2018 |
Pharmacologic prevention of variceal bleeding and rebleeding.
Topics: Adrenergic beta-Antagonists; Atorvastatin; Carbazoles; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hemodynamics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Portal; Incidence; Liver; Liver Cirrhosis; Nitric Oxide Synthase Type III; Portal Pressure; Propanolamines; Propranolol; Simvastatin; Splanchnic Circulation | 2018 |
[Latest advances in acute pancreatitis].
Topics: Aneurysm, False; Clostridioides difficile; Clostridium Infections; Combined Modality Therapy; Comorbidity; Diabetes Mellitus; Drainage; Fat Necrosis; Heparin, Low-Molecular-Weight; Humans; Liver Cirrhosis; Multiple Organ Failure; Nutritional Support; Obesity; Pancreatitis, Acute Necrotizing; Positron Emission Tomography Computed Tomography; Severity of Illness Index; Simvastatin | 2015 |
9 trial(s) available for simvastatin and Cirrhosis, Liver
| Article | Year |
|---|---|
Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis.
Topics: Acute-On-Chronic Liver Failure; Carnitine; Humans; Kynurenine; Liver Cirrhosis; Metabolomics; Rifaximin; Simvastatin; Tryptophan | 2022 |
Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Gastrointestinal Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Portal; Liver Cirrhosis; Portal Pressure; Rifaximin; Simvastatin; Treatment Outcome | 2020 |
Hemodynamic Effects of Adding Simvastatin to Carvedilol for Primary Prophylaxis of Variceal Bleeding: A Randomized Controlled Trial.
Topics: Adrenergic beta-Antagonists; Adult; Carvedilol; Drug Therapy, Combination; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Hemodynamics; Hepatic Veins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Cirrhosis; Male; Middle Aged; Portal Pressure; Primary Prevention; Simvastatin; Treatment Outcome; Venous Pressure | 2020 |
Safety of Chronic Simvastatin Treatment in Patients with Decompensated Cirrhosis: Many Adverse Events but No Liver Injury.
Topics: Argentina; Cardiovascular Diseases; Disease Progression; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Diseases; Headache; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Cirrhosis; Male; Middle Aged; Myalgia; Outcome and Process Assessment, Health Care; Risk Assessment; Severity of Illness Index; Simvastatin | 2021 |
SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation.
Topics: Esophageal and Gastric Varices; Fibrosis; Gastrointestinal Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Cirrhosis; Liver Neoplasms; Prospective Studies; Retrospective Studies; Simvastatin | 2021 |
Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: A randomized controlled trial.
Topics: Aged; Double-Blind Method; Endosonography; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Portal; Liver Cirrhosis; Male; Middle Aged; Portal Pressure; Simvastatin; Treatment Outcome; Ultrasonography, Doppler, Color; Venous Pressure | 2015 |
Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis.
Topics: Adrenergic beta-Antagonists; Aged; Combined Modality Therapy; Double-Blind Method; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Ligation; Liver Cirrhosis; Male; Middle Aged; Proportional Hazards Models; Recurrence; Rhabdomyolysis; Risk Factors; Simvastatin; Spain; Time Factors; Treatment Outcome | 2016 |
Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Double-Blind Method; Female; Hemodynamics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Portal; Hypolipidemic Agents; Liver Circulation; Liver Cirrhosis; Male; Middle Aged; Portal Pressure; Simvastatin | 2009 |
Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis.
Topics: Adult; Aged; Double-Blind Method; Female; Hemodynamics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Circulation; Liver Cirrhosis; Male; Middle Aged; Nitric Oxide; Postprandial Period; Simvastatin; Vascular Resistance; Vasomotor System; Venous Pressure | 2004 |
28 other study(ies) available for simvastatin and Cirrhosis, Liver
| Article | Year |
|---|---|
Improved anti-fibrotic effects by combined treatments of simvastatin and NS-398 in experimental liver fibrosis models.
Topics: Animals; Cyclooxygenase 2 Inhibitors; Hepatic Stellate Cells; Liver; Liver Cirrhosis; Mice; Nitrobenzenes; Simvastatin; Sulfonamides; Thioacetamide | 2022 |
Sequential Nano-Penetrators of Capillarized Liver Sinusoids and Extracellular Matrix Barriers for Liver Fibrosis Therapy.
Topics: Capillaries; Collagenases; Endothelial Cells; Extracellular Matrix; Hepatic Stellate Cells; Humans; Hyaluronic Acid; Liver; Liver Cirrhosis; Simvastatin; Vitamin A | 2022 |
Incorporation and Performance Verification of Hepatic Portal Blood Flow Shunting in Minimal and Full PBPK Models of Liver Cirrhosis.
Topics: Buspirone; Humans; Liver Cirrhosis; Midazolam; Models, Biological; Propranolol; Simvastatin | 2023 |
When less is more: dosing simvastatin in decompensated cirrhosis.
Topics: Double-Blind Method; Humans; Liver Cirrhosis; Rifaximin; Simvastatin | 2020 |
Dead Meat: Glecaprevir/Pibrentasvir-Induced Statin Myonecrosis.
Topics: Antiviral Agents; Benzimidazoles; Biopsy; Coronary Artery Disease; Drug Combinations; Drug Interactions; Hepatitis C, Chronic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Cirrhosis; Male; Middle Aged; Myalgia; Pyrrolidines; Quinoxalines; Rhabdomyolysis; Simvastatin; Sulfonamides | 2020 |
Simvastatin-loaded polymeric micelles are more effective and less toxic than conventional statins in a pre-clinical model of advanced chronic liver disease.
Topics: Animals; Disease Models, Animal; Drug Delivery Systems; Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Cirrhosis; Micelles; Polymers; Rats; Simvastatin; Tissue Distribution | 2020 |
Statins in liver cirrhosis in a developing country: benefits overweigh the risk?
Topics: Chemical and Drug Induced Liver Injury; Contraindications, Drug; Developing Countries; Hepatitis, Viral, Human; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver Cirrhosis; Meta-Analysis as Topic; Non-alcoholic Fatty Liver Disease; Obesity; Peru; Risk Assessment; Simvastatin | 2020 |
Lycopene corrects metabolic syndrome and liver injury induced by high fat diet in obese rats through antioxidant, anti-inflammatory, antifibrotic pathways.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Blood Glucose; Chemical and Drug Induced Liver Injury; Cytokines; Diet, High-Fat; Fibrinolytic Agents; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Lipid Metabolism; Lipids; Liver Cirrhosis; Lycopene; Male; Metabolic Syndrome; Obesity; Rats; Rats, Wistar; Simvastatin; Weight Gain | 2021 |
Synergistic effects of simvastatin and bone marrow-derived mesenchymal stem cells on hepatic fibrosis.
Topics: Animals; Bone Marrow Transplantation; Cells, Cultured; Combined Modality Therapy; Drug Synergism; Liver Cirrhosis; Liver Function Tests; Male; Mesenchymal Stem Cell Transplantation; Rats; Rats, Sprague-Dawley; Simvastatin; Treatment Outcome | 2018 |
Simvastatin Prevents Progression of Acute on Chronic Liver Failure in Rats With Cirrhosis and Portal Hypertension.
Topics: Animals; End Stage Liver Disease; Hepatic Stellate Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Portal; Lipopolysaccharides; Liver Circulation; Liver Cirrhosis; Liver Failure, Acute; Male; Oxidative Stress; Rats; Rats, Sprague-Dawley; Rats, Wistar; Simvastatin | 2018 |
NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients.
Topics: Adult; Aged; Aged, 80 and over; Biopsy; Cause of Death; Chi-Square Distribution; Decision Support Techniques; Fatty Liver; Female; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Liver Cirrhosis; Logistic Models; Male; Metformin; Middle Aged; Minnesota; Multivariate Analysis; Non-alcoholic Fatty Liver Disease; Odds Ratio; Predictive Value of Tests; Prognosis; Risk Factors; Severity of Illness Index; Simvastatin; Time Factors; Young Adult | 2013 |
The therapeutic effects of bone marrow-derived mesenchymal stem cells and simvastatin in a rat model of liver fibrosis.
Topics: Animals; Bone Marrow Cells; Collagen Type I; Collagen Type II; Disease Models, Animal; Endoglin; Female; Gene Expression Regulation; Hypolipidemic Agents; Intracellular Signaling Peptides and Proteins; Liver; Liver Cirrhosis; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Rats; Rats, Wistar; Severity of Illness Index; Sex-Determining Region Y Protein; Simvastatin; Tissue Inhibitor of Metalloproteinase-1 | 2014 |
Simvastatin ameliorates liver fibrosis via mediating nitric oxide synthase in rats with non-alcoholic steatohepatitis-related liver fibrosis.
Topics: Actins; Animals; Cells, Cultured; Collagen Type I; Diet, High-Fat; Enzyme Inhibitors; Fatty Liver; Gene Expression; Hepatic Stellate Cells; Humans; Hypolipidemic Agents; Liver; Liver Cirrhosis; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Non-alcoholic Fatty Liver Disease; Rats; Rats, Wistar; Simvastatin; Transforming Growth Factor beta1 | 2013 |
KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins.
Topics: Animals; Antifibrinolytic Agents; Cells, Cultured; Disease Models, Animal; Gene Expression Regulation; Hepatic Stellate Cells; Humans; Kruppel-Like Transcription Factors; Liver Cirrhosis; Male; Molecular Targeted Therapy; Phenotype; Protective Agents; Random Allocation; Rats; Rats, Wistar; Sensitivity and Specificity; Simvastatin; Up-Regulation | 2015 |
Liver: Sussing out statins in cirrhosis--KLF2 is the key.
Topics: Animals; Hepatic Stellate Cells; Humans; Kruppel-Like Transcription Factors; Liver Cirrhosis; Male; Simvastatin | 2015 |
Statins, Rho GTPases and KLF2: new mechanistic insight into liver fibrosis and portal hypertension.
Topics: Animals; Hepatic Stellate Cells; Humans; Kruppel-Like Transcription Factors; Liver Cirrhosis; Male; Simvastatin | 2015 |
[Statin against cirrhosis].
Topics: Adenoviridae; Animals; Cells, Cultured; Disease Models, Animal; Gene Knockout Techniques; Genetic Vectors; Hepatitis C, Chronic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kruppel-Like Transcription Factors; Liver Cirrhosis; Nitric Oxide; Rats; Simvastatin | 2015 |
Therapies: Drugs, Scopes and Transjugular Intrahepatic Portosystemic Shunt--When and How?
Topics: Adrenergic beta-Antagonists; Antibiotic Prophylaxis; Anticholesteremic Agents; Balloon Occlusion; Combined Modality Therapy; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; Ligation; Liver Cirrhosis; Portasystemic Shunt, Transjugular Intrahepatic; Simvastatin; Stents | 2015 |
Simvastatin Attenuates Liver Injury in Rodents with Biliary Cirrhosis Submitted to Hemorrhage/Resuscitation.
Topics: Animals; Gastrointestinal Hemorrhage; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Cirrhosis; Liver Cirrhosis, Biliary; Male; Rats; Simvastatin | 2017 |
Altered Pharmacokinetics of Statins Explain Increased Risk of Rhabdomyolysis in Advanced Cirrhosis.
Topics: Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Cirrhosis; Rhabdomyolysis; Risk; Simvastatin | 2016 |
Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin with rapamycin plus tacrolimus in liver transplant patient.
Topics: Acute Kidney Injury; Anticholesteremic Agents; Drug Therapy, Combination; Fatal Outcome; Hepatitis C; Humans; Hypertension; Immunosuppressive Agents; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Mycophenolic Acid; Postoperative Complications; Rhabdomyolysis; Simvastatin; Tacrolimus | 2009 |
The role of nitric oxide in the expression of renal aquaporin 2 in a cirrhotic rat model: does an AVP-independent mechanism exist for the regulation of AQP2 expression?
Topics: Analysis of Variance; Animals; Aquaporin 2; Biopterins; Cyclic GMP; Disease Models, Animal; Immunoenzyme Techniques; Isosorbide Dinitrate; Kidney; Liver Cirrhosis; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Random Allocation; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Simvastatin; Statistics, Nonparametric; Thioacetamide | 2010 |
Fatal rhabdomyolysis in a patient with liver cirrhosis after switching from simvastatin to fluvastatin.
Topics: Coronary Artery Disease; Fatal Outcome; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver Cirrhosis; Male; Middle Aged; Rhabdomyolysis; Simvastatin | 2011 |
[Simvastatin inhibits activation of hepatic stellate cells and promotes activation of adenosine monophosphate-activated protein kinase].
Topics: Adenylate Kinase; Animals; Cell Line; Fatty Liver; Hepatic Stellate Cells; Humans; Liver Cirrhosis; Male; Rats; Rats, Wistar; Simvastatin | 2012 |
Effect of HMG-CoA reductase inhibitors on proliferation and protein synthesis by rat hepatic stellate cells.
Topics: Animals; Cell Division; Collagen Type I; Collagen Type III; Collagen Type IV; Fibronectins; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Liver; Liver Cirrhosis; Lovastatin; Male; Membrane Proteins; Phenotype; ras Proteins; Rats; Rats, Wistar; rhoA GTP-Binding Protein; Simvastatin | 2003 |
Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats.
Topics: Animals; Anticholesteremic Agents; Carbon Tetrachloride; Cyclic GMP; Liver; Liver Cirrhosis; Liver Diseases; Male; Nitric Oxide; Nitric Oxide Synthase Type III; Perfusion; Phosphorylation; Rats; Rats, Wistar; Simvastatin | 2007 |
Petechial eruptions due to simvastatin in a patient with diabetes mellitus and liver cirrhosis.
Topics: Anticholesteremic Agents; Biopsy, Needle; Diabetes Mellitus, Type 1; Humans; Hypercholesterolemia; Japan; Liver Cirrhosis; Lovastatin; Male; Middle Aged; Purpura; Simvastatin | 1997 |
Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin.
Topics: Aged; Anticholesteremic Agents; Antioxidants; Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Disease Progression; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia; Hypoglycemic Agents; Liver Cirrhosis; Myositis; Simvastatin; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |